Cerave Face Soin Concentré Anti-Imperfections Blemished and acne-prone skin 40ml

CERAVE
Concentrated Anti-Imperfection Care
AHA BHA and 3 Essential Ceramides
Imperfections and acne-prone skin
40ml

Developed with dermatologists, CeraVe Blemish Control Concentrate removes imperfections for acne-prone skin.
Moisturises, soothes and restores your cutaneous barrier.
Based on a powerful concentrate of AHA-BHA (alpha hydroxy acids - beta hydroxy acids known for their exfoliating properties), works both in depth and on the surface, preventing blemish reappearance.
- AHA: Glycolic Acid + Lactic Acid: removes dead skin cells and blemishes while reducing inflammation.
- BHA: 2% Salicylic Acid: unclogs and tightens pores, smoothes and improves skin texture.

Cerave daily anti-acne treatment enriched with 3 essential Ceramides, Niacinamide, & Hyaluronic Acid, moisturizes for 8 hours*, restoring your cutaneous barrier.
Thanks to a patented MVE® Technology, ensures a prolonged diffusion of active ingredients and a lasting 24 hour action.
Its fresh gel texture is quickly absorbed by your skin for a non-greasy, non-sticky effect.
This high tolerance formula, tested under dermatological control, respects a strict sensitive skin charter.
Fragrance-free, alcohol-free, hypoallergenic, physiological ph and non-comedogenic.
Suitable for daily use by adolescents and adults.

Instrumental test, corneometer hydration measurement. Clinically proven anti-acne efficiency.
Significant results after only 3 days of use:
-45% reduced acne lesions.
- 90% softer skin
- 78% smoother and refined texture
- 72% fewer blemishes and acne spots
- 80% satisfaction with the product

Significant anti-acne efficacy clinically proven after 4 weeks of use: on open comedones (blackheads), inflammatory lesions, redness, papules and pustules.
Your skin is smoother, pores are tightened.
Clinical study in monotherapy, men and women, 13-45 years, oily skin, acne-prone skin (mild to moderate), 1 facial use per day in the evening + SPF 30 cream each morning. Medical evaluation at 3 days, 2, 4 & 8 weeks of use. N=52 patients.
Measurement & clinical evaluation of inflammatory lesions. Patient self-assessment.